Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HumanZyme and PacificGMP have entered into a collaboration agreement to manufacture GMP-certified growth factors and cytokines for use in human cell therapy applications.
Subscribe to our email newsletter
Growth factors and cytokines, which are proteins, will help researchers to convert stem cells into specific cell types for repairing damaged cells of heart or restoring cellular functions that have been lost in diabetes syndrome and Parkinson’s disease.
Under the agreement, HumanZyme will provide HumanKine growth factors and cytokines to PacificGMP to manufacture recombinant human proteins intended for human clinical use.
HumanZyme CEO Scott Coleridge said PacificGMP has a manufacturing facility for manufacturing clinical grade proteins in large quantities that are needed to support the demand generated by an approved therapy.
"We are making our proprietary technology available to PacificGMP to enable the production of our HumanKine growth factors and cytokines which will help allow regenerative medicine companies to advance development of stem cell therapies," Coleridge added.
PacificGMP CEO Gary Pierce said HumanZyme’s production cell lines and culture conditions have the necessary features for easy adaption to a GMP environment.
"In addition, the human cells, the serum-free cell culture, and a completely animal component-free process will help ensure that the manufactured proteins are both bioactive and safe; we are pleased that PacificGMP is contributing to the advancement of much needed human cellular therapies, " Pierce added.